Core Insights - The article discusses the establishment and significance of the National Key Laboratory for Bioactive Molecules and Drugability Optimization, which aims to enhance the biopharmaceutical industry in Guangdong Province, a key area for future competitiveness in China [3][4]. Group 1: Laboratory Overview - The laboratory, led by Professor Ye Wencai, includes over 150 researchers, with more than 40 being national-level talents, and aims to create a world-class source for innovative drug transformation [5]. - It was officially approved for construction in March 2023, addressing challenges in original innovation for major diseases and enhancing China's pharmaceutical technology strength [4][5]. Group 2: Research and Development Methodology - The laboratory employs a unique research paradigm based on "phenotype" or "phenotype + target" for drug development, leveraging China's rich resources in traditional Chinese medicine and natural drugs [6]. - This approach allows for the direct screening of active ingredients from traditional medicine and their optimization based on target confirmation, significantly improving the success rate of new drug development [6][7]. Group 3: Technological Innovations - The laboratory has established a complete technical chain from discovery to evaluation, including strategies for efficient discovery of bioactive molecules, optimization of lead compounds, and advanced manufacturing techniques [7][8]. - Key technologies developed include a new strategy for directional discovery of natural compounds, optimization techniques for drugability, and the establishment of various large animal disease models for research [7][8]. Group 4: Industry Impact and Collaboration - The laboratory's research pipeline covers multiple drug development areas, including tissue repair, anti-tumor, anti-viral, and neurological diseases, with several new drugs already approved for market [9][10]. - It has positively influenced over 30 biopharmaceutical companies, incubated four listed companies, and contributed over 20 billion yuan in new value to related enterprises in the past five years [10]. Group 5: Recommendations for Industry Development - To promote high-quality development in Guangdong's biopharmaceutical industry, it is recommended to strengthen source innovation, support long-term investments, and fill gaps in the industrial chain [11]. - The establishment of a talent mechanism that attracts interdisciplinary professionals and a results-oriented evaluation system is crucial for enhancing research and development [11].

Group 1 - Shouyao Holdings is planning to issue H-shares and list on the Hong Kong Stock Exchange, with discussions ongoing with intermediaries regarding the specifics of the listing [1] - Jiangsu Guoxin's subsidiary, Guoxin Mazhou, has completed the trial operation of a 1000MW coal-fired power unit, which is set to officially commence operations on December 12, 2025 [2] - Yuekang Pharmaceutical's mRNA tumor vaccine has received clinical trial approval from the National Medical Products Administration for treating advanced solid tumors [3] Group 2 - Dongli New Science plans to invest 666 million yuan in the restructuring of SAIC Hongyan, acquiring approximately 14.66% equity post-restructuring [4] - Longsheng Technology is set to invest approximately 350 million yuan in the establishment of an intelligent robot innovation center in Wuxi [5] - Shangwei Co. has received a government subsidy of 2.212 million yuan, which accounts for 13.53% of its audited net profit for 2024 [6] Group 3 - Anglikang has received drug registration certificates for Diclofenac Sodium Enteric-Coated Tablets and approval for a supplemental application for Sacubitril/Valsartan Sodium Tablets [7] - Guangzhou Development has received acceptance notices for the registration of 8 billion yuan in medium-term notes and 6 billion yuan in short-term financing bonds [8] - Kebo Da plans to increase capital by 21.2 million euros (approximately 174 million yuan) in its wholly-owned subsidiary in Germany [9][10] Group 4 - Changguang Huaxin has received a total of 11.6672 million yuan in government subsidies, including 8.0552 million yuan related to income [11] - Haizheng Pharmaceutical's subsidiary has received a European Pharmacopoeia suitability certificate for its raw material [12] - Qianjin Pharmaceutical's subsidiary has received a drug registration certificate for Lurasidone Hydrochloride Tablets, used for treating schizophrenia [13] Group 5 - Daimai Co. has received a warning letter from the Shanghai Securities Regulatory Bureau due to failure to timely disclose a significant event related to a fire incident [14] - ST Changyao's subsidiary has recently ceased production due to financial difficulties and competitive pressures in the photovoltaic industry [15] - Guodian Power is investing in the construction of a 2×1000MW expansion project at the Ganbi Power Plant, with a total dynamic investment of 7.218 billion yuan [16] Group 6 - Kaichuang International's subsidiary has completed the handover of a tuna purse seine vessel, expected to be operational by 2026 [16] - Tieke Rail plans to sign an energy management agreement for a distributed photovoltaic project, which is expected to save approximately 1.441 million yuan in electricity costs over 25 years [18] - Bailian Co. plans to sign a land compensation agreement with Friendship Logistics, with a total compensation of 103 million yuan [19] Group 7 - Dayu Water-saving's subsidiary has been pre-awarded two high-standard farmland construction projects, with total expected amounts of 137 million yuan and 135 million yuan respectively [20] - Tianma Technology reported a total eel output of approximately 1197.15 tons in November, with sales prices ranging from 53,000 yuan/ton to 89,000 yuan/ton [21] - Guorui Technology's subsidiary has been shortlisted for the GXLF project with a bid of 76 million yuan [22] Group 8 - Qingdao Food's deputy general manager has resigned for personal reasons [23] - Guosheng Zhike plans to use up to 900 million yuan of idle funds for cash management [24] - Guodian Nanrui plans to use up to 23 billion yuan of idle funds for entrusted wealth management [25] Group 9 - Jiahuan Energy plans to merge its wholly-owned subsidiary, Zhejiang Jiahuan Hydrogen Peroxide Co., Ltd., through an overall absorption merger [26] - Ganyue Expressway reported vehicle toll service revenue of 309 million yuan for November [27] - Jinling Hotel's chairman has resigned due to work changes [28] Group 10 - Lisheng Pharmaceutical's subsidiary has received drug registration certificates for Apremilast Tablets [29] - Baotai has received a positive opinion from the European Medicines Agency for Gotenfia® for various inflammatory conditions [30] - ST Zhisheng has been awarded a smart city governance project with a bid amount of 104 million yuan [31] Group 11 - Chenxi Aviation and its related personnel have received administrative regulatory measures from the Shaanxi Securities Regulatory Bureau due to financial reporting issues [32] - Portong Medical has appointed Xia Canglan as the new deputy general manager [33] - Maide Medical plans to repurchase shares with a total amount between 20 million and 40 million yuan [34] Group 12 - Jimin Health plans to establish a joint venture with a total investment of 600 million yuan, focusing on AI and software development [35] - Beilu Pharmaceutical has received a drug registration certificate for Pioglitazone Metformin Tablets [36] - Hainan Mining plans to entrust the overall management of the Shiluo Iron Mine to a construction company for three years, with a total contract amount of approximately 818 million yuan [38] Group 13 - Huiyu Pharmaceutical has received a drug registration certificate for Nicardipine Hydrochloride Injection [39] - Baoland has received a government subsidy of 10 million yuan related to income [40] - Qingdao Port has terminated the acquisition of 100% equity in an oil company and 50% equity in Rizhao Shihua due to regulatory concerns [41]

来源：智通财经网 百奥泰(688177.SH)发布公告，公司于近日收到了欧洲药品管理局(以下简称"EMA")的通知， Gotenfia®(BAT2506，戈利木单抗注射液)获得EMA人用药品委员会(以下简称"CHMP")积极意见。 CHMP建议欧盟委员会(EC)批准Gotenfia®上市，用于治疗类风湿关节炎，幼年特发性关节炎，银屑病 关节炎，中轴型脊柱关节炎，溃疡性结肠炎。 BAT2506是百奥泰根据中国国家药品监督管理局(以下简称"NMPA")、美国食品药品监督管理局(以下简 称"FDA")、EMA生物类似药相关指导原则开发的戈利木单抗生物类似药。戈利木单抗是靶向TNF-α的 抗体，能够以高亲和力特异性地结合可溶性及跨膜的人TNF-α，阻断TNF-α与其受体TNFR结合，从而 抑制TNF-α的活性。 BAT2506(戈利木单抗注射液)的原研药为美国强生公司的Simponi® (欣普尼®)。根据强生公司2024年年 度报告，Simponi®2024年在全球的销售额为21.90亿美元。 ...

格隆汇12月12日丨百奥泰(688177.SH)公布，公司于近日收到了欧洲药品管理局（以下简称"EMA"）的 通知，Gotenfia®（BAT2506，戈利木单抗注射液）获得EMA人用药品委员会（以下简称"CHMP"）积 极意见。CHMP建议欧盟委员会（EC）批准Gotenfia®上市，用于治疗类风湿关节炎，幼年特发性关节 炎，银屑病关节炎，中轴型脊柱关节炎，溃疡性结肠炎。 ...

二、 药品其他相关情况 百奥泰生物制药股份有限公司 自愿披露关于 Gotenfia ®（戈利木单抗注射液）获欧 洲药品管理局人用药品委员会积极意见的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 百奥泰生物制药股份有限公司（以下简称"百奥泰"或"公司"）于近日收到 了欧洲药品管理局（以下简称"EMA"）的通知，Gotenfia®（BAT2506，戈利木 单抗注射液）获得EMA人用药品委员会（以下简称"CHMP"）积极意见。 CHMP建议欧盟委员会（EC）批准Gotenfia®上市，用于治疗类风湿关节炎，幼 年特发性关节炎，银屑病关节炎，中轴型脊柱关节炎，溃疡性结肠炎。 现将相关情况公告如下： 一、 药品相关情况 （四） 适应症：类风湿关节炎，幼年特发性关节炎，银屑病关节炎，中轴 型脊柱关节炎，溃疡性结肠炎 证券代码：688177 证券简称： 百奥泰 公告编号：2025-069 BAT2506 是百奥泰根据中国国家药品监督管理局（以下简称"NMPA"）、 美国食品药品监督管理局（以下简称"FDA"）、EMA 生物类似药 ...

BAT2506(戈利木单抗注射液)的原研药为美国强生公司的Simponi® (欣普尼®)。根据强生公司2024年年 度报告，Simponi®2024年在全球的销售额为21.90亿美元。 BAT2506是百奥泰根据中国国家药品监督管理局(以下简称"NMPA")、美国食品药品监督管理局(以下简 称"FDA")、EMA生物类似药相关指导原则开发的戈利木单抗生物类似药。戈利木单抗是靶向TNF-α的 抗体，能够以高亲和力特异性地结合可溶性及跨膜的人TNF-α，阻断TNF-α与其受体TNFR结合，从而 抑制TNF-α的活性。 智通财经APP讯，百奥泰(688177.SH)发布公告，公司于近日收到了欧洲药品管理局(以下简称"EMA")的 通知，Gotenfia®(BAT2506，戈利木单抗注射液)获得EMA人用药品委员会(以下简称"CHMP")积极意 见。 CHMP建议欧盟委员会(EC)批准Gotenfia®上市，用于治疗类风湿关节炎，幼年特发性关节炎，银 屑病关节炎，中轴型脊柱关节炎，溃疡性结肠炎。 ...

格隆汇12月12日丨百奥泰(688177.SH)公布，公司于近日收到了欧洲药品管理局（以下简称"EMA"）的 通知，Gotenfia®（BAT2506，戈利木单抗注射液）获得EMA人用药品委员会（以下简称"CHMP"）积 极意见。CHMP建议欧盟委员会（EC）批准Gotenfia®上市，用于治疗类风湿关节炎，幼年特发性关节 炎，银屑病关节炎，中轴型脊柱关节炎，溃疡性结肠炎。 ...

格隆汇12月12日丨百奥泰(688177.SH)公布，公司于近日收到了欧洲药品管理局（以下简称"EMA"）的 通知，Gotenfia（BAT2506，戈利木单抗注射液）获得EMA人用药品委员会（以下简称"CHMP"）积极 意见。CHMP建议欧盟委员会（EC）批准Gotenfia上市，用于治疗类风湿关节炎，幼年特发性关节炎， 银屑病关节炎，中轴型脊柱关节炎，溃疡性结肠炎。 （原标题：百奥泰(688177.SH)：Gotenfia®（戈利木单抗注射液）获欧洲药品管理局人用药品委员会积 极意见） ...

百奥泰公告，近日收到欧洲药品管理局（EMA）的通知，Gotenfia®（BAT2506，戈利木单抗注射液） 获得EMA人用药品委员会（CHMP）积极意见。CHMP建议欧盟委员会（EC）批准Gotenfia®上市，用 于治疗类风湿关节炎、幼年特发性关节炎、银屑病关节炎、中轴型脊柱关节炎、溃疡性结肠炎。 ...

Core Viewpoint - The stock of Baiotai has experienced a decline recently, with a notable drop in trading volume and a significant outflow of funds, despite a year-to-date increase in stock price [1][2]. Group 1: Stock Performance - Baiotai's stock price decreased by 2.01% to 24.35 CNY per share, with a trading volume of 22.72 million CNY and a turnover rate of 0.22% [1]. - Year-to-date, Baiotai's stock has risen by 25.64%, but it has seen a decline of 2.60% over the last five trading days, 8.25% over the last 20 days, and 29.87% over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Baiotai achieved a revenue of 684 million CNY, representing a year-on-year growth of 17.57% [2]. - The net profit attributable to the parent company was -224 million CNY, showing a year-on-year increase of 38.72% [2]. Group 3: Company Overview - Baiotai Biopharmaceutical Co., Ltd. is located in Guangzhou, Guangdong Province, and was established on July 28, 2003, with its stock listed on February 21, 2020 [2]. - The company's main business involves the research and production of innovative drugs and biosimilars, with revenue composition as follows: 91.90% from drug sales, 6.55% from licensing, 0.90% from contract manufacturing, and 0.65% from technical services [2]. Group 4: Shareholder Information - As of September 30, 2025, Baiotai had 9,397 shareholders, a decrease of 0.89% from the previous period, with an average of 44,065 circulating shares per shareholder, an increase of 0.89% [2]. - Hong Kong Central Clearing Limited is the tenth largest circulating shareholder, holding 6.0247 million shares as a new shareholder [2].